Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Jul 26;4(2):64-9.
doi: 10.1159/000354066. eCollection 2013.

Intravitreal Injection of Dexamethasone Implant in Serous Macular Detachment Associated with Waldenström's Disease

Vito Fenicia  1 , Marco Balestrieri, Andrea Perdicchi, Giorgia Maraone, Santi Maria Recupero
Affiliations
Case Reports

Intravitreal Injection of Dexamethasone Implant in Serous Macular Detachment Associated with Waldenström's Disease

Vito Fenicia et al. Case Rep Ophthalmol. .

Abstract

Purpose: To evaluate the efficacy of one intravitreal injection of dexamethasone (Ozurdex(®); Allergan, Inc., Irvine, Calif., USA) in serous macular detachment (SMD) of one eye, associated with bilateral central retinal vein occlusion (CRVO) in a patient affected by Waldenström's macroglobulinemia (WM).

Patients and methods: A female patient, affected by WM, complained of a progressive decrease in visual acuity, mainly in the left eye (LE). SMD in the LE associated with bilateral CRVO was diagnosed. One intravitreal injection of dexamethasone was administered in the LE and the patient was tested 1, 2, and 6 months after the injection.

Results: 1, 2, and 6 months after the injection, the spectral domain optical coherence tomography (SD-OCT) showed a progressive slight reduction of foveal thickness that was not related to any improvement of visual function.

Conclusions: Treatment with dexamethasone (Ozurdex) induced a progressive slight reduction of SMD but no improvement of visual acuity, and it is possible that this is related to the condition of hematic hyperviscosity that is present in WM.

Keywords: Dexamethasone; Intravitreal injection; Serous macular detachment; Waldenström's macroglobulinemia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
FAG, infrared reflectance, and SD-OCT of the left eye before treatment (foveal thickness 858 µm).
Fig. 2
Fig. 2
SD-OCT of the left eye 1 month after Ozurdex (foveal thickness 686 µm).
Fig. 3
Fig. 3
SD-OCT of the left eye 2 months (upper panel) and 6 months (lower panel) after Ozurdex (foveal thickness 680 µm and 547 µm, respectively).
See this image and copyright information in PMC

References

    1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30:110–115. - PubMed
    1. Avashia JH, Fath DF. Bilateral central retinal vein occlusion in Waldenström's macroglobulinemia. J Am Optom Assoc. 1989;60:657–658. - PubMed
    1. Fadilah SA, Muhaya M, Azlin I. Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenström's macroglobulinemia. Med J Malaysia. 2007;62:349–351. - PubMed
    1. Casares PZ, Gillet DS, Verity DH, Rowson NR. Bilateral simultaneous central retinal vein occlusion (CRVO) caused by Waldenström's macroglobulinaemia with acquired Von Willebrand's disease. Br J Haematol. 2002;118:344–347. - PubMed
    1. Nabet L, Dufier JL, Cornu P, Junghers P, Chauvin JC, de Monteynard MS, et al. Bilateral occlusion of the central vein of the retina disclosing Waldenström's disease. Bull Soc Ophthalmol Fr. 1989;89:39–41. - PubMed

Publication types

LinkOut - more resources